Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 14/20 | 0.80 |
| ▸ | MAPT | P10636 | 12/20 | 0.80 |
| ▸ | HTT | P42858 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 4/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2153930 | 0.89 | ALDH1A1 (1.00) | ALDH1A1MAPTHTTLMNATDP1 | |
| SCHEMBL13836489 | 0.89 | ALDH1A1 (0.80) | ALDH1A1MAPTHTTLMNATDP1 | |
| SCHEMBL15502403 | 0.86 | MAPT (1.00) | ALDH1A1MAPTHTTLMNATDP1 | |
| SCHEMBL2153853 | 0.81 | ALDH1A1 (1.00) | ALDH1A1MAPTHTTLMNATDP1 | |
| SCHEMBL2153964 | 0.81 | ALDH1A1 (0.78) | ALDH1A1MAPTHTTLMNATDP1 | |
| SCHEMBL2153257 | 0.78 | ALDH1A1 (0.77) | ALDH1A1MAPTHTTLMNATDP1 | |
| SCHEMBL2153109 | 0.78 | ALDH1A1 (1.00) | ALDH1A1MAPTHTTLMNATDP1 | |
| SCHEMBL11058028 | 0.77 | FLT1 (0.68) | ALDH1A1MAPTHTTTDP1KMT2A | |
| SCHEMBL10680090 | 0.76 | ALDH1A1 (1.00) | ALDH1A1MAPTHTTLMNATDP1 | |
| SCHEMBL2153023 | 0.76 | MEN1 (0.76) | ALDH1A1MAPTLMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295890-A1 | GLYCOSAMINOGLYCAN INHIBITORS | Zacharon Pharmaceutical, Inc. (US) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295890-A1 | GLYCOSAMINOGLYCAN INHIBITORS | CSGALNACT1, FUT5, ST3GAL3 | ALDH1A1 797/4885MAPT 4328/4885HTT 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.